pre-IPO PHARMA

COMPANY OVERVIEW

Third Pole, Inc. is a US-based company developing next generation life-saving cardiopulmonary therapies. We are building on our team’s legacy in inhaled nitric oxide (NO), the current standard of care, to develop next generation life-saving heart and lung therapies. Our first product is being designed to be a simple, convenient, economical, and lightweight device capable of generating nitric oxide from air and electricity (eNO) on-demand and on-site which potentially eliminates the need for large compressed gas cylinders. We believe our novel approach of creating NO on demand from iridium electrodes (eNO) has the promise to create new markets by enabling the worldwide use of inhaled NO in settings outside of acute care.


LOCATION

  • Arlington, MA, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Respiratory Disease

  • WEBSITE

    http://www.pole3.com


    CAREER WEBSITE

    http://www.pole3.com/company/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Apr 15, 2021

    Third Pole Therapeutics Secures $15 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.


    Feb 24, 2021

    Third Pole Therapeutics Expands Board of Directors


    Apr 8, 2020

    Third Pole Therapeutics Announces Global Commercialization Agreement with Chiesi Group for Its Tankless, Portable Inhaled Nitric Oxide (iNO) Delivery System


    Dec 20, 2019

    Third Pole Therapeutics To Present at Biotech Showcase 2020


    Oct 30, 2019

    Third Pole Therapeutics Names Bill Athenson New CEO


    For More Press Releases


    Google Analytics Alternative